Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826627 | 0.88 | OPRM1 (0.71) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL1625785 | 0.86 | OPRM1 (0.47) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL1611 | 0.84 | OPRM1 (0.67) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL7377089 | 0.84 | OPRM1 (0.67) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL626042 | 0.83 | OPRM1 (0.65) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL31441136 | 0.83 | OPRM1 (0.65) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL10052501 | 0.83 | OPRM1 (0.57) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL625403 | 0.81 | OPRM1 (0.58) | OPRM1OPRL1 | |
| SCHEMBL14441345 | 0.81 | OPRM1 (0.58) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL13253741 | 0.81 | OPRM1 (0.58) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | OPRM1 3044/4885SLC6A4 4113/4885SLC6A3 3829/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | OPRM1 3044/4885SLC6A4 4113/4885SLC6A3 3829/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | OPRM1 121/4885SLC6A4 511/4885SLC6A3 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.